Skip to main content
TLSI
NASDAQ Life Sciences

TriSalus Life Sciences 超出2025年收入指导，实现53%增长，第四季度亏损收窄

feedReported by Dow Jones Newswires
Sentiment info
Positive
Importance info
8
Price
$4.77
Mkt Cap
$285.301M
52W Low
$3.42
52W High
$7.95
Market data snapshot near publication time

summarizeSummary

TriSalus Life Sciences 公布了强劲的2025年第四季度和全年财务业绩，超出其2025年收入指导。该公司在第四季度实现了1320万美元的收入，同比增长60%，全年收入达4520万美元，代表着53%的增长，超过其50%的指导。调整后的 EBITDA 亏损大幅收窄至2025年第四季度的90万美元，较前一年570万美元大幅减少。该公司还重申了其2026年收入指导，预计收入为6000-6200万美元，这得益于最近一次公开募股所获得的4600万美元的净收益，这之前曾在二月下旬的 SEC 文件中披露。这种强劲的表现和加强的资产负债表为持续增长和商业扩张提供了资本，表明公司的发展势头为正。

在该公告发布时，TLSI的交易价格为$4.77，交易所为NASDAQ，所属行业为Life Sciences，市值约为$2.9亿。 52周交易区间为$3.42至$7.95。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：Dow Jones Newswires。

show_chartPrice Chart

Share this article

Copied!

feed TLSI - Latest Insights

TLSI
Apr 29, 2026, 4:32 PM EDT
Filing Type: 8-K
Importance Score:
7
Chief of Clinical Operations to Retire from TriSalus Life Sciences
Sentiment: Negative
View Wiseek Article
TLSI
Apr 07, 2026, 9:10 AM EDT
Filing Type: 8-K
Importance Score:
7
TriSalus Life Sciences Appoints Dr. Richard Marshall as Chief Medical Officer
Sentiment: Positive
View Wiseek Article
TLSI
Mar 30, 2026, 6:17 PM EDT
Filing Type: DEF 14A
Importance Score:
8
TriSalus Life Sciences Discloses Substantial Executive Compensation Amidst Net Losses and Going Concern Warning
Sentiment: Negative
View Wiseek Article
TLSI
Mar 05, 2026, 4:08 PM EST
Filing Type: 10-K
Importance Score:
7
TriSalus Life Sciences Reports Strong Revenue Growth Amidst Increased Losses, Going Concern Warning, and Material Weakness
Sentiment: Neutral
View Wiseek Article
TLSI
Mar 05, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
8
TriSalus Life Sciences Exceeds 2025 Revenue Guidance, Narrows Losses, and Reaffirms 2026 Outlook
Sentiment: Positive
View Wiseek Article
TLSI
Mar 05, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
8
TriSalus Life Sciences Exceeds 2025 Revenue Guidance with 53% Growth, Narrows Q4 Loss
Sentiment: Positive
View Wiseek Article
TLSI
Feb 23, 2026, 4:08 PM EST
Filing Type: 4
Importance Score:
7
CEO Buys $125K in Shares at Public Offering Price Following Recent Capital Raise
Sentiment: Positive
View Wiseek Article
TLSI
Feb 23, 2026, 4:08 PM EST
Filing Type: 4
Importance Score:
8
Director Michael Stansky Buys $1.48M in Shares at Public Offering Price Following Recent Dilution
Sentiment: Positive
View Wiseek Article
TLSI
Feb 20, 2026, 4:30 PM EST
Filing Type: 424B5
Importance Score:
8
TriSalus Life Sciences Prices $40M Public Offering at a Significant Discount
Sentiment: Negative
View Wiseek Article
TLSI
Feb 20, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
8
TriSalus Life Sciences Prices Highly Dilutive Public Offering at Significant Discount
Sentiment: Negative
View Wiseek Article